Vonderheide RH - Search Results

1

Melanoma inhibitor of apoptosis protein (ML-IAP) is a target for immune-mediated tumor destruction.

Schmollinger JC, Vonderheide RH, Hoar KM, Maecker B, Schultze JL, Hodi FS, Soiffer RJ, Jung K, Kuroda MJ, Letvin NL, Greenfield EA, Mihm M, Kutok JL, Dranoff G. Schmollinger JC, et al. Among authors: vonderheide rh. Proc Natl Acad Sci U S A. 2003 Mar 18;100(6):3398-403. doi: 10.1073/pnas.0530311100. Epub 2003 Mar 7. Proc Natl Acad Sci U S A. 2003. PMID: 12626761 Free PMC article.

2

The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes.

Vonderheide RH, Hahn WC, Schultze JL, Nadler LM. Vonderheide RH, et al. Immunity. 1999 Jun;10(6):673-9. doi: 10.1016/s1074-7613(00)80066-7. Immunity. 1999. PMID: 10403642 Free article.

3

Immunoglobulin framework-derived peptides function as cytotoxic T-cell epitopes commonly expressed in B-cell malignancies.

Trojan A, Schultze JL, Witzens M, Vonderheide RH, Ladetto M, Donovan JW, Gribben JG. Trojan A, et al. Among authors: vonderheide rh. Nat Med. 2000 Jun;6(6):667-72. doi: 10.1038/76243. Nat Med. 2000. PMID: 10835683

4

Tumour immunotherapy: new tools, new treatment modalities and new T-cell antigens.

Schultze JL, Maecker B, von Bergwelt-Baildon MS, Anderson KS, Vonderheide RH. Schultze JL, et al. Among authors: vonderheide rh. Vox Sang. 2001 Feb;80(2):81-9. doi: 10.1046/j.1423-0410.2001.00014.x. Vox Sang. 2001. PMID: 11378969 Review.

5

Generation of cytotoxic T lymphocytes against native and altered peptides of human leukocyte antigen-A*0201 restricted epitopes from the human epithelial cell adhesion molecule.

Trojan A, Witzens M, Schultze JL, Vonderheide RH, Harig S, Krackhardt AM, Stahel RA, Gribben JG. Trojan A, et al. Among authors: vonderheide rh. Cancer Res. 2001 Jun 15;61(12):4761-5. Cancer Res. 2001. PMID: 11406549

6

From cancer genomics to cancer immunotherapy: toward second-generation tumor antigens.

Schultze JL, Vonderheide RH. Schultze JL, et al. Among authors: vonderheide rh. Trends Immunol. 2001 Sep;22(9):516-23. doi: 10.1016/s1471-4906(01)02015-4. Trends Immunol. 2001. PMID: 11525943 Review.

7

CD40 activation of carcinoma cells increases expression of adhesion and major histocompatibility molecules but fails to induce either CD80/CD86 expression or T cell alloreactivity.

Vonderheide RH, Butler MO, Liu JF, Battle TE, Hirano N, Gribben JG, Frank DA, Schultze JL, Nadler LM. Vonderheide RH, et al. Int J Oncol. 2001 Oct;19(4):791-8. doi: 10.3892/ijo.19.4.791. Int J Oncol. 2001. PMID: 11562757

8

Characterization of HLA-A3-restricted cytotoxic T lymphocytes reactive against the widely expressed tumor antigen telomerase.

Vonderheide RH, Anderson KS, Hahn WC, Butler MO, Schultze JL, Nadler LM. Vonderheide RH, et al. Clin Cancer Res. 2001 Nov;7(11):3343-8. Clin Cancer Res. 2001. PMID: 11705846

9

Equivalent induction of telomerase-specific cytotoxic T lymphocytes from tumor-bearing patients and healthy individuals.

Vonderheide RH, Schultze JL, Anderson KS, Maecker B, Butler MO, Xia Z, Kuroda MJ, von Bergwelt-Baildon MS, Bedor MM, Hoar KM, Schnipper DR, Brooks MW, Letvin NL, Stephans KF, Wucherpfennig KW, Hahn WC, Nadler LM. Vonderheide RH, et al. Cancer Res. 2001 Dec 1;61(23):8366-70. Cancer Res. 2001. PMID: 11731409

10

Linking genomics to immunotherapy by reverse immunology--'immunomics' in the new millennium.

Maecker B, von Bergwelt-Baildon, Anderson KS, Vonderheide RH, Schultze JL. Maecker B, et al. Among authors: vonderheide rh. Curr Mol Med. 2001 Nov;1(5):609-19. doi: 10.2174/1566524013363447. Curr Mol Med. 2001. PMID: 11899235 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

213 results

Search Page

Filters